Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects
| Autor: | Prashant Kapoor, Saurabh Zanwar, Shivani Seth, Linh Vu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Population Disease Monoclonal Gammopathy of Undetermined Significance Risk Assessment 03 medical and health sciences 0302 clinical medicine Risk Factors immune system diseases hemic and lymphatic diseases Internal medicine Biomarkers Tumor Tumor Microenvironment Humans Medicine Genetic Predisposition to Disease cardiovascular diseases education Multiple myeloma education.field_of_study Hematology business.industry Geriatrics gerontology medicine.disease Clinical trial 030220 oncology & carcinogenesis Disease Progression Related disorder Multiple Myeloma Transcriptome business Precancerous Conditions Monoclonal gammopathy of undetermined significance 030215 immunology |
| Zdroj: | Current Hematologic Malignancy Reports. 15:45-55 |
| ISSN: | 1558-822X 1558-8211 |
| Popis: | Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent precursor condition in the general population, with an approximate 1% annual risk of progression to multiple myeloma (MM) or a related disorder. Our understanding of MGUS and its association with myriad clinical disorders, its progression to MM, and the genomic alterations in the setting of a conducive or permissive microenvironment has deepened considerably. Data from gene expression profiling studies have underscored the heterogeneity in the risk of progression of MGUS to MM. Ongoing efforts are being directed toward precise identification of high-risk factors for progression and addressing the role of screening for MGUS in populations at higher risk of MGUS in order to diagnose this precursor condition early, and target modifiable risk factors. Ongoing clinical trials are assessing the role of therapeutic interventions to prevent MGUS from progressing. MGUS is a heterogeneous precursor condition with a risk for progression to symptomatic disease. Future directions are focusing on identifying high-risk populations of MGUS and smoldering multiple myeloma that may benefit with screening and/or early intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink